Abstract
Although proteomics is a very recently developed science, important advances have already occurred in this field. There is growing interest in the scientific community for using this technology as a high-throughput innovative strategy for biomarker discovery in the field of cancer research. However, certain challenges must be overcome before reaching this goal. The basis for discovering reliable biomarkers is rooted in technical and biological parameters. The main biological limit is outlining tumor heterogeneity, while methodological issues include appropriate study designs, the use of sensitive technologies for screening, and the employment of confident strategies for data validation. This review focuses on the major questions related to the strengths and limitations of the development of cancer biomarkers by proteomic- based studies.
Keywords: Biomarkers, cancer, design of studies, mass spectrometry, proteomics, tumor heterogeneity.
Current Proteomics
Title:How can Proteomics Reach Cancer Biomarkers?
Volume: 10 Issue: 2
Author(s): Carolina Panis, Luciana Pizzatti and Eliana Abdelhay
Affiliation:
Keywords: Biomarkers, cancer, design of studies, mass spectrometry, proteomics, tumor heterogeneity.
Abstract: Although proteomics is a very recently developed science, important advances have already occurred in this field. There is growing interest in the scientific community for using this technology as a high-throughput innovative strategy for biomarker discovery in the field of cancer research. However, certain challenges must be overcome before reaching this goal. The basis for discovering reliable biomarkers is rooted in technical and biological parameters. The main biological limit is outlining tumor heterogeneity, while methodological issues include appropriate study designs, the use of sensitive technologies for screening, and the employment of confident strategies for data validation. This review focuses on the major questions related to the strengths and limitations of the development of cancer biomarkers by proteomic- based studies.
Export Options
About this article
Cite this article as:
Panis Carolina, Pizzatti Luciana and Abdelhay Eliana, How can Proteomics Reach Cancer Biomarkers?, Current Proteomics 2013; 10 (2) . https://dx.doi.org/10.2174/1570164611310020006
DOI https://dx.doi.org/10.2174/1570164611310020006 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Multiple Target-Specific Molecular Agents for Detection and Image Analysis of Breast Cancer Characteristics in Mice
Current Molecular Medicine Interaction Between Retinoids and Eicosanoids: Their Relevance to Cancer Chemoprevention
Current Nutrition & Food Science Efficacy of Yun Zhi (Coriolus versicolor) on Survival in Cancer Patients: Systematic Review and Meta-Analysis
Recent Patents on Inflammation & Allergy Drug Discovery Recent Advances in Characterizing Natural Products that Regulate Autophagy
Anti-Cancer Agents in Medicinal Chemistry Treatment for Radiation-Induced Pulmonary Late Effects: Spoiled for Choice or Looking in the Wrong Direction?
Current Drug Targets Immune Responses to Lentiviral Vectors
Current Gene Therapy Brain Targeted Drug Delivery: Factors, Approaches and Patents
Recent Patents on Nanomedicine Ethosomes as Vesicles for Effective Transdermal Delivery: From Bench to Clinical Implementation
Current Clinical Pharmacology Pharmacological Inhibitors of Fatty Acid Synthase (FASN)-Catalyzed Endogenous Fatty Acid Biogenesis: A New Family of Anti-Cancer Agents?
Current Pharmaceutical Biotechnology Will Arsenic Trioxide Benefit Treatment of Solid Tumor by Nano- Encapsulation?
Mini-Reviews in Medicinal Chemistry Strategies on the Development of Small Molecule Anticancer Drugs for Targeted Therapy
Mini-Reviews in Medicinal Chemistry Role of the Immune Component of Tumor Microenvironment in the Efficiency of Cancer Treatment: Perspectives for the Personalized Therapy
Current Pharmaceutical Design Increased Tumor Oxygenation and Drug Uptake During Anti-Angiogenic Weekly Low Dose Cyclophosphamide Enhances the Anti-Tumor Effect of Weekly Tirapazamine (Supplementry Material)
Current Cancer Drug Targets Tamoxifen: A Synthetic Overview
Current Organic Chemistry Synthesis and Cytotoxicity of 4-(2-Adamantyl)phenylalkylamines
Letters in Organic Chemistry Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Evaluation of In-Vivo Anti-Implantation and In-Vitro Anti-Proliferative Activities of Substituted 3-phenyl-4-phenylvinyl Benzopyranone Derivatives
Letters in Drug Design & Discovery Molecular Mistletoe Therapy: Friend or Foe in Established Anti-Tumor Protocols? A Multicenter, Controlled, Retrospective Pharmaco-Epidemiological Study in Pancreas Cancer
Current Molecular Medicine Strategies for Stalling Malignancy: Targeting Cancers Addiction to Hsp90
Current Topics in Medicinal Chemistry Central Nervous System Vasculitis: Still More Questions than Answers
Current Neuropharmacology